{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039389","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.594775+00:00","generated_at":"2026-06-12T02:06:40.528035+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cogent Q2 net loss $44.1M, cash $350.9M, PEAK DCR 55%, FGFR2 candidate nominated","bullets":["Cash & equivalents $350.9M at June 30 (up from $220.3M on Mar 31); funded into 2026.","Net loss Q2 2023: $44.1M vs $34.9M Q2 2022; R&D $38.9M vs $29.5M.","Phase 3 PEAK lead-in data: 55% DCR; 100% DCR and 17% ORR in evaluable 2nd-line GIST patients.","Selected FGFR2 kinase inhibitor as first internally developed candidate; preclinical data planned for 2H2023.","Initial SUMMIT (NonAdvSM) and updated APEX (AdvSM) data expected in second half of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039389","json":"https://secwatch.observer/filing/0000950170-23-039389.json","markdown":"https://secwatch.observer/filing/0000950170-23-039389.md","text":"https://secwatch.observer/filing/0000950170-23-039389.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000095017023039389/0000950170-23-039389-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000095017023039389/cogt-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:06:40.528035+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b307b84bbbd3383cff977fb68709b8624e5e10c5","claim":"Cogent Biosciences, Inc. reported the second quarter ended June 30, 2023 results: net income $44.1 million.","evidence_excerpt":"Net loss was $44.1 million for the second quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1622229/000095017023039389/0000950170-23-039389-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"$44.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}